Yan Leyfman, MD

Thank you to @i24News for highlighting our latest #COVID__19 work and my journey as a Chernobyl survivor. #COVID19 youtu.be/8-lw1OeC_60

🧬 From Precision to Universality: A New Frontier in Cancer Immunotherapy While most oncology startups chase ever-more targeted treatments, Dispatch Bio is flipping the script—developing a universal immunotherapy to attack any solid tumor. Their strategy? A synthetic “flare”…

🧬✨ Hope Through Mitochondrial Donation A UK reproductive program offering pronuclear transfer (a form of mitochondrial donation) to women with pathogenic mtDNA variants has resulted in 8 healthy live births. 🔹 All infants had no or low mtDNA heteroplasmy 🔹 Minor postnatal…

🧠💪 Creatine: More Than Just Muscle Fuel? Beyond boosting strength, lean mass, and performance, creatine may also support cognitive health via the muscle-brain axis 🧬. Emerging research suggests it influences myokines—notably BDNF—linking muscle activity to neuroprotection and…

🧬🔥 New Study Unveils Role of Autoantibodies in Cancer Immunotherapy Response While cellular immunity is key to checkpoint inhibitor (CPI) therapy, the impact of humoral immunity has remained underexplored—until now. A groundbreaking analysis of >6,000 extracellular proteins…

💪 Protein Timing Debate: 3 vs. 5 Meals? New study shows that when total daily protein intake is matched, the distribution across meals (3 vs. 5) doesn't significantly impact gains in muscle mass or strength in resistance-trained young men. 📊 After 8 weeks: ➡️ Both groups saw…

Cancer doesn’t just change your blood tests. It changes your calendar, your language, your priorities… and no one is ever ready for that.

🚨 Pioneering study from Dr. Chrystal Paulos (Emory Univ) & team reveals a critical partnership between Th17 cells and host B cells in adoptive T cell therapy (ACT) against melanoma. 🧠 Key Highlights: • Host B cells are essential for tumor regression by Th17 cells • Th17…

This last weekend in July, spend some time W @JasmineKambojMD on #HUExpress advising Hem/Onc fellows starting training this month. "How to Survive & Thrive in fellowship?" @HemOncFellows @TheFellowOnCall @IMG_Oncologists @ASCO @Noha_Soror @marklewismd @docbraunstein @VincentRK

New Study Alert 🚨 Our latest transcriptomic analysis investigates immune and cellular dysregulation in individuals who developed adverse events or new-onset cancer following mRNA COVID-19 vaccination. 🧬 Key Findings: Shared signatures of mitochondrial dysfunction, ribosomal…

🫁 Can a Digital Asthma Self-Management (DASM) Program Improve Symptom Control? ✅ Yes—but effectiveness varies by population. In a randomized trial of 901 adults, those using a DASM app (with symptom tracking, notifications & wearables) had significantly better asthma control…

Excellent summary of our work - IgRT (IgG replacement therapy, including IVIG and SCIG) has a long and largely disappointing history in myeloma #MMsm…. But the risk-benefit calculus is very different when it comes to bsAbs given their infection risk!

🧠 Managing Infection Risk in Myeloma: Time to Rethink IgRT? Bispecific antibodies (bsAbs) like teclistamab, elranatamab, talquetamab, and linvoseltamab are transforming multiple myeloma treatment—but bring a persistent risk of infection. 📉 Enter immunoglobulin replacement…

🧬 DLBCL: A Complex Puzzle, A New Era of Solutions 🔍 Diffuse large B-cell lymphoma (DLBCL) is a biologically diverse and aggressive lymphoma shaped by genetic drivers and its tumor microenvironment—both influencing disease course and therapeutic response. Great review led by…

💡 Can less be more? A new study from City of Hope shows that a reduced starting dose of hepatic arterial infusion (HAI) floxuridine (0.08 mg/kg/day) significantly lowers hepatobiliary toxicity without compromising survival in patients with completely resected colorectal liver…

🚨 Ambient AI scribes are going mainstream — but will small practices be left behind? Over the past 2 years, ambient AI scribes have exploded in health care, promising to ease charting burdens. But steep costs and lack of EHR integration still leave many small or safety-net…

AI and Innovation in Oncology targetedonc.com/view/ai-and-in… via @targetedonc

🧬 Boosting CAR-T/NK Cell Persistence via the FAS Pathway Chimeric antigen receptor (CAR) T and NK cell therapies have transformed treatment for B-cell malignancies—but limited cell persistence remains a key barrier. 🧪 In a new study led by Dr. Christopher A. Klebanoff,…

🧠 Can we skip full prostate MRIs with a single clean sequence? A new study of 492 prostate MRIs (PI-RADS v2.1 compliant) investigated whether a negative T2WI or DWI alone can reliably predict a completely negative scan. 🔍 Key findings: ✅ A negative DWI predicted a negative…

💥New paper out! We reanalyzed raw sequencing data from 18,558 standard-of-care Guardant360 ctDNA assays in advanced #colorectalcancer using a partner-agnostic fusion caller. 🧬 Fusions in 1.3% of patients 🧪 93% were subclonal — enriched after EGFR therapy 🔗 Clonal fusions…